Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Lab21 promotes its expanding range of immunodiagnostic products at Arab Health with a new Human ...


Lab21 promotes its expanding range of immunodiagnostic products at Arab Health with a new Human Cytomegalovirus immunoassay

Cambridge, UK, 16 January 2009 … Lab21 is pleased to announce that it will be exhibiting at this year’s Arab Health Conference in Dubai where both its Diagnostic Services and Immunodiagnostic Products division will be represented. This important regional exhibition will help raise the profile of Lab21 as it expands its diagnostics businesses internationally and provide the Company with the launch platform for its new Human Cytomegalovirus (HCMV) EIA assay. Graham Mullis CEO of Lab21 said, “This event provides Lab21 with the opportunity to show-case how Lab21 can be the partner of choice for the region with its quality infectious disease immunodiagnostic product offering and wide range of oncology and personalised medicine services. The Company is already able to provide cost-effective services with rapid turnaround times for patients in the region that need access to state-of-the-art diagnostics.”

Lab21 will use this event to provide preliminary details on the new HCMV EIA assay, the latest new product from the Immunodiagnostic Division. HCMV is a virus in the Herpes virus group, which generally has no symptoms even after infection. However, it can prove dangerous for pre and post natal infants and in immuno-compromised patients.

Dr. Berwyn Clarke CSDO stated that, “Initial data shows that the Lab21 HCMV assay is very easy to use with exceptional sensitivity and specificity profiles and seems to be able to detect serum HCMV antibodies earlier than our competitors. This product is already generating considerable interest from our current customers and has the potential to be the gold standard test for this disease area.”

Further to its international expansion strategy, Lab21’s Immunodiagnostic Division has also recently secured a number of major new tenders to supply its diagnostic products to Non Governmental Organisations (NGO) in Africa and Thailand to add to the successful recent Indian market launch of its Syphilis assay.

Stephen Hembling International Sales Manager said that, “This hard earned success has put the company in a strong position for 2009. We intend to use these NGO tenders as a means to access new markets and further support our aggressive growth plans for existing and new products.” Please visit Lab21 at ARAB Health at stand MJ18.

About Lab21
Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting drug discovery and healthcare. Its customers include healthcare providers, pharmaceutical and biotechnology companies. The Company has a growing test portfolio providing companion diagnostics and high technology assays for the growing integration of personalised medicine into healthcare. These services and products are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease.

Lab21's clinical reference laboratory and corporate office is based in Cambridge, UK and the Company's investors include Merlin Biosciences, Nexus Medical Partners, Rowan Dartington and Kreos Capital.

Website: www.lab21.com Contacts at Lab21:

Media relations for Lab21:
College Hill

Tony Stephenson
Rebecca Walker
Sue Charles
t : +44 (0) 20 7866 7864
e: lab21@collegehill.com

At Lab21:
Graham Mullis, CEO
Dr Berwyn Clarke, CSDO
t : +44 (0)1223 395450
e: graham.mullis@lab21.com or berwyn.clarke@lab21.com


Publisher Contact Information:

Lab21
+44 (0)1223 395450
graham.mullis@lab21.com

Company profile of Lab21
Past press releases of Lab21.

Data


26,442
Tech investments
From our Online Data Service
17,073
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 6€9.3MSoftware development
Dec 6€1.5MConsumer applications
Dec 6€3.7MInternet commerce
Dec 5€8.0MNanotechnology
Dec 5€11.0MBiotechnology
Dec 5€11.0MRobotics
Dec 5N/ARobotics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.